Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Greater fatigue, disturbed sleep, persistent memory problems, and reduced CD4 T cell and B cell percentages in adults with a history of methamphetamine dependence.
J Neuroimmunol
February 2025
Department of Psychiatry, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA; Research & Development Service, Veterans Affairs Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd, Portland, OR 97239, USA; Mental Health and Clinical Neurosciences Division, Veterans Affairs Portland Health Care System, 3710 SW U.S. Veterans Hospital Rd, Portland, OR 97239, USA; Department of Behavioral Neuroscience, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA. Electronic address:
Methamphetamine (MA) dependence is associated with immunotoxicity and high rates of neuropsychiatric impairments that persist into remission. Although there are currently no FDA-approved pharmacotherapies for MA use disorders, preclinical and clinical studies are beginning to test interventions that directly impact immune signaling. This study was conducted to investigate the relative contribution of immune cell function to the neuropsychiatric sequelae associated with MA dependence and remission.
View Article and Find Full Text PDFVirally mediated expression of a biologically active peptide to restrain the nuclear functions of ERK1/2 attenuates learning extinction but not acquisition.
Mol Brain
March 2025
Center for Gene Manipulation in the Brain, University of Haifa, Haifa, Israel.
Peptide drug technologies offer powerful approaches to develop potent and selective lead molecules for therapeutic and research applications. However, new and optimized delivery approaches are necessary to overcome current pitfalls including fast degradation in cells and tissue. Extracellular signal-regulated kinases 1/2 (ERK1/2) exemplifies proteins that play crucial and varied roles within distinct cellular compartments.
View Article and Find Full Text PDFAssociations of depressive symptoms and cortisol with cognitive performance among memory clinic patients.
Int Psychogeriatr
March 2025
Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences, and Society, Karolinska Institutet, Stockholm, Sweden; Cognitive Disorders Clinic, Theme Inflammation and Aging, Karolinska University Hospital, Stockholm, Sweden. Electronic address:
Objective: Test the hypothesis that depressive symptoms are associated with cognitive performance and that cortisol levels may explain this association independently of Alzheimer's Disease (AD) biomarker levels.
Design: Longitudinal observational study.
Setting: Memory clinic, Karolinska University Hospital, Stockholm, Sweden.
Associations between cerebrospinal fluid synaptic protein biomarkers and cognitive function in bipolar disorder.
J Psychiatr Res
March 2025
Copenhagen Affective Disorder Research Center (CADIC), Psychiatric Center Copenhagen, Department Frederiksberg, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Denmark.
This study is the first to investigate the association between a comprehensive panel of cerebrospinal fluid (CSF) synaptic protein biomarkers and cognitive function using data from a prospective cohort study including N = 59 patients with bipolar disorder (BD) in remission and N = 37 healthy control individuals (HC). The CSF synaptic protein biomarkers included neuronal pentraxin (NPTX)1, NPTX2, 14-3-3 proteins, AP-2 complex subunit-beta, beta-synuclein, complexin-2, gamma-synuclein, NPTX-receptor, phosphatidylethanolamine-binding proteins, rab GDP dissociation inhibitor-alpha, syntaxins-1B and 7. The biomarkers of synaptic dysfunction were analyzed by targeted mass spectrometry.
View Article and Find Full Text PDFChemotherapy-related cognitive impairment and kidney dysfunction.
Nephrol Dial Transplant
March 2025
Department of Translational Medical Sciences, University of Campania "Luigi Vanvitelli", Caserta, Italy.
Cancer and kidney diseases (KD) intersect in many ways resulting in worse outcomes. Both conditions are correlated with cognitive impairment, which can be exacerbated in cancer patients by known effects of many antineoplastic drugs on cognition, leading to a phenomenon known as chemotherapy-related cognitive impairment (CRCI). This manifests as poor attention span, disturbed short-term memory, and general mental sluggishness.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!